Response of liver to glucocorticoid is altered by administration of shosaikoto (kampo medicine).
The effects of Shosaikoto, one of the Kampo medicines used for therapy for chronic hepatitis, on liver functions were studied in mice. Oral administration of Shosaikoto for 5 d enhanced the well-known induction of tyrosine aminotransferase (TAT) activity by dexamethasone. Further, TAT activity in mice treated with Shosaikoto was induced effectively by a smaller dose of dexamethasone, as compared with that in control mice. However, Shosaikoto itself did not induce TAT activity in the liver on oral administration or in cultured hepatocytes by direct addition. Moreover, Shosaikoto did not affect the induction of TAT activity by butyryl-adenosine 3',5'-cyclic monophosphate. The amplifying effect of Shosaikoto seemed to be specific for induction by dexamethasone. These data suggest that Shosaikoto makes the liver sensitive to glucocorticoid by some unknown mechanism.